Jacobs Journal of Cancer Science and Research

Immunotherapeutic Approach to Osteosarcoma

*Timothy Allen
Department Of Oncology, Enter For Excellence In Research And Development, United States

*Corresponding Author:
Timothy Allen
Department Of Oncology, Enter For Excellence In Research And Development, United States
Email:Timothy.Allen@gapsos.com

Published on: 2017-02-03

Abstract

Osteosarcoma is a rare form of cancer that account for less than 0.2% of all cancers diagnosed in the United States. Unfortunately, the cause is unknown, but there have been several risks factors accused of causing the disease such as genetics, Paget disease, exposure to radiation or chemicals, and bone marrow transplants. Immunotherapy is a cancer treatment alternative to chemotherapy and radiation therapy. Its goal is to use a patient’s own immune system to fight the tumor. The patient’s immune system is stimulated by exposing synthetic immune molecules into their system. In this paper, we discuss the potential causes of osteosarcomas, the pathophysiology of the disease, and potential ways to cure the disease using different immunotherapy techniques.

Keywords

Bone Cancer; Immunotherapy; Chondrosarcoma; Osteosarcoma

Introduction

Bone cancer is a rare cancer, which occurs due to the unwanted growth of cells in the bone tissues. In 2014, the American Cancer Society estimated that there were 3,020 (1,680 men and 1,340 in women) new cases of bone cancer and 1,460 (830 men and 630 among women) deaths caused by bone cancer in the United States. In adults, over 40% of primary bone cancers are osteosarcoma, which is less than 0.2% of all types of cancer. In children and teenagers (those younger than 20 years), osteosarcoma (56%) and Ewing Sarcoma (34%) are much more common than chondrosarcoma (6%).